Inavolisib [2060571-02-8]
Cat# T15375-5mg
Size : 5mg
Brand : TargetMol
Inavolisib
(Synonyms: RG6114, GDC-0077) Copy Product Info
Inavolisib (GDC-0077) is an orally available selective PI3Kα inhibitor with an IC50 value of 0.038 nM.It exerts its activity by binding to the ATP-binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3.
Cas No. 2060571-02-8
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.96%
COA HNMR LCMS
Product Information
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Inavolisib (GDC-0077) is an orally available selective PI3Kα inhibitor with an IC50 value of 0.038 nM.It exerts its activity by binding to the ATP-binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3. |
| Targets & IC50 | PI3Kα:0.038 nM, HCC1954 cells:60 nM, MCF-7 cells:30 nM |
| In vitro | METHODS: Cell viability was assayed using Inavolisib (GDC-00777) up to 100 μmol/L in a panel of cancer cell lines. RESULTS Inavolisib (GDC-00777) is a stronger cellular antiproliferative inducer. [1] |
| In vivo | METHODS: p110a protein depletion was studied in a p110a mutant xenograft breast cancer model using Inavolisib (GDC-0077) at a single oral dose of 50 mg/kgDC-0077. RESULTS Inavolisib (GDC-0077) depleted p110a protein expression for up to 8 hours. [1] |
| Synonyms | RG6114, GDC-0077 |
| Molecular Weight | 407.37 |
| Formula | C18H19F2N5O4 |
| Cas No. | 2060571-02-8 |
| Smiles | C[C@H](Nc1ccc2-c3nc(cn3CCOc2c1)N1[C@@H](COC1=O)C(F)F)C(N)=O |
| Relative Density. | 1.63 g/cm3 (Predicted) |
| Storage | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||
| Solubility Information | DMSO: 240 mg/mL (589.15 mM), Sonication is recommended.  | ||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (24.55 mM), Solution. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||
Solution Preparation Table | |||||||||||||
DMSO
| |||||||||||||